BRAF and thyroid cancer: Combined inhibition of BRAF and HER3 using Vemurafenib and the human monoclonal antibody CDX-3379, respectively, would restore radioiodine (RAI) avidity by potently inhibiting MAPK activation in patients with BRAF-mutant iodine refractory thyroid cancer [47].